Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,402 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer Metastatic Breast Cancer Clear all

Conditions: Advanced Breast Cancer
Interventions: ARV-471, Fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Encinitas, California • Fountain Valley, California • Fresno, California + 69 more

Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: Sacituzumab govitecan, Naxitamab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: MEDI-573, Aromatase Inhibitor; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 34
States / cities: Scottsdale, Arizona • Bakersfield, California • Pleasant Hill, California + 28 more

Conditions: Breast Cancer
Interventions: Dasatinib and Paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Neoplasms
Interventions: Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 15
States / cities: La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more

Conditions: Metastatic Cancer, Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Tumor, Metastatic Tumor of Bone, Metastatic Tumor to the Spine, Spine Metastases, Metastasis
Interventions: SBRT to the spine; Radiation
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Metastatic Breast Cancer
Interventions: 17B-estradiol, Letrozole, Anastrozole, Exemestane; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 3
States / cities: Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire

Conditions: Metastatic Breast Cancer
Interventions: Capecitabine, Oxaliplatin, Trastuzumab; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 11
States / cities: Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 6 more

Conditions: Breast Cancer
Interventions: Alpelisib, Sacituzumab govitecan; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more

Conditions: Metastatic Breast Cancer
Interventions: Pegylated liposomal doxorubicin, Capecitabine; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 60 Years and older · Female only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 27
States / cities: Fountain Valley, California • Oxnard, California • Soquel, California + 24 more

Conditions: Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Bortezomib, Fulvestrant, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 21
States / cities: Farmington, Connecticut • New Haven, Connecticut • Weston, Florida + 8 more

Conditions: Estrogen Receptor-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: saracatinib, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Pembrolizumab, Propranolol, Questionnaire Administration; Procedure · Biological · Drug + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Atlanta, Georgia • Buffalo, New York

Conditions: Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
Interventions: Virtually Supervised Exercise Sessions, Asynchronous Group; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions: ²¹²Pb-DOTAM-GRPR1; Drug
Lead sponsor: Orano Med Theranostics, SAS; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 8
States / cities: Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more

Conditions: Metastatic Breast Cancer, Lobular Breast Carcinoma
Interventions: Blood Specimen; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2036
U.S. locations: 4
States / cities: San Diego, California • San Francisco, California • Philadelphia, Pennsylvania + 1 more

Conditions: HER2-expressing Cancers
Interventions: ZW49; Drug
Lead sponsor: Zymeworks BC Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Chicago, Illinois + 5 more

Conditions: Breast Cancer
Interventions: Crixotinib 200 mg and Sunitinib Cohort 1, Crixotinib 250 mg and Sunitinib Cohort 2, Crizotinib & Sunitinib 37.5 mg Cohort 3; Drug
Lead sponsor: Mothaffar Rimawi; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: TAS-108; Drug
Lead sponsor: SRI International; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications
Interventions: zoledronic acid; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 503
States / cities: Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more

Conditions: HER-2 Positive Metastatic Breast Cancer
Interventions: Etoposide, Trastuzumab; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Metastatic Breast Cancer, Brain Metastases
Interventions: Pembrolizumab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 19 Years to 90 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 3
States / cities: New York, New York

Conditions: Estrogen Receptor Positive Breast Cancer
Interventions: hydroxychloroquine; Drug
Lead sponsor: Western Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Goodyear, Arizona

Conditions: Breast Cancer
Interventions: AC699; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • Orlando, Florida • Sarasota, Florida + 6 more

Search by objective public record fields.

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Definitive Radiation for High-Risk Spine Metastases

ER Reactivation Therapy for Breast Cancer

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

Survivors Uniting for Remote Guided Exercise

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer

Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy

Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer